CHARACTERISTICS	Nº	%
Male	4	40%
Female	6	60%
Median age at diagnosis, (range), years	9.22	(7-12)
Status of disease
2 o + 3 relapse	6	60%
Refractory to primary or salvage therapy	4	40%
Complete remission after Blinatumomab	7	70%
Partial remission after Blinatumomab	1	10%
Active disease	2	20%